These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 18067048)

  • 1. Calcium channels blockers and progression of kidney disease.
    Ziakka S; Kaperonis N; Ferentinou E; Karakasis F; Ntatsis G; Kourvelou C; Papagalanis N
    Ren Fail; 2007; 29(8):1003-12. PubMed ID: 18067048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
    Abe M; Okada K; Maruyama T; Maruyama N; Matsumoto K
    Hypertens Res; 2009 Apr; 32(4):270-5. PubMed ID: 19262495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients/a retrospective, "real-world" comparative study.
    Yamada H; Suga N; Maeda K; Kimura Y; Miura N; Futenma A; Imai H
    Arzneimittelforschung; 2010; 60(2):64-70. PubMed ID: 20329653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease.
    Abe M; Okada K; Maruyama N; Matsumoto S; Maruyama T; Fujita T; Matsumoto K; Soma M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1027-37. PubMed ID: 20649501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of renal disease--can it be reversed? The role of calcium channel blockers and angiotensin-converting enzyme inhibitors.
    Boner G
    Isr J Med Sci; 1996 Dec; 32(12):1217-21. PubMed ID: 9007157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
    Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
    Verdecchia P; Angeli F; Cavallini C; Gattobigio R; Gentile G; Staessen JA; Reboldi G
    Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Management of hypertension in CKD patients].
    Kusaba T; Kimura K
    Nihon Rinsho; 2008 Sep; 66(9):1747-52. PubMed ID: 18788405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease.
    Tomino Y; Shimizu Y; Hamada C; Kurusu A; Ohsawa I; Suzuki Y; Tsuge T; Io H; Kobayashi N; Takeda Y; Asanuma K; Tanaka Y; Suzuki H; Nakata J; Takara K; Horikoshi S
    J Nephrol; 2011; 24(6):756-63. PubMed ID: 21360472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial.
    Boero R; Rollino C; Massara C; Vagelli G; Gonella M; Berto IM; Bajardi P; Perosa P; Malcangi U; Giorgi MP; Ghezzi PM; Borzumati M; Baroni AM; Cogno C; Triolo G; Angelini D; Antonelli A; Quarello F
    J Nephrol; 2001; 14(1):15-8. PubMed ID: 11281338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients.
    Yang Y; Wei RB; Xing Y; Tang L; Zheng XY; Wang ZC; Gao YW; Li MX; Chen XM
    Metabolism; 2013 Dec; 62(12):1858-66. PubMed ID: 24050270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN).
    Ruggenenti P; Perna A; Benini R; Remuzzi G
    J Am Soc Nephrol; 1998 Nov; 9(11):2096-101. PubMed ID: 9808096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease.
    Omae K; Ogawa T; Nitta K
    Heart Vessels; 2009 Jul; 24(4):301-7. PubMed ID: 19626404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria.
    Saito F; Fujita H; Takahashi A; Ichiyama I; Harasawa S; Oiwa K; Takahashi N; Otsuka Y; Uchiyama T; Kanmatsuse K; Kushiro T
    Hypertens Res; 2007 Jan; 30(1):39-47. PubMed ID: 17460370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal and cardiovascular effects of angiotensin-converting enzyme inhibitor plus angiotensin II receptor antagonist therapy in children with proteinuria.
    Lubrano R; Soscia F; Elli M; Ventriglia F; Raggi C; Travasso E; Scateni S; Di Maio V; Versacci P; Masciangelo R; Romero S
    Pediatrics; 2006 Sep; 118(3):e833-8. PubMed ID: 16923922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis.
    Ishimitsu T; Kameda T; Akashiba A; Takahashi T; Ohta S; Yoshii M; Minami J; Ono H; Numabe A; Matsuoka H
    Hypertens Res; 2007 Jul; 30(7):621-6. PubMed ID: 17785930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
    Zhao HJ; Li Y; Liu SM; Sun XG; Li M; Hao Y; Cui LQ; Wang AH
    Ren Fail; 2016 Jul; 38(6):849-56. PubMed ID: 27055479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slowing nephropathy progression: focus on proteinuria reduction.
    Bakris GL
    Clin J Am Soc Nephrol; 2008 Jan; 3 Suppl 1(Suppl 1):S3-10. PubMed ID: 18178794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.